

Jim Collins: Good to Great virtual event.

Subscribers save \$150 on tickets.

Book now FINANCIAL REVIEW

Advertisement


Policy

Health And Education

Coronavirus pandemic

Print article

Is remdesivir more powerful against COVID-19 than first thought?



Jill Margo

Health editor

Jul 20, 2020 - 3.57pm


[Save](#)[Share](#)

Remdesivir, the first antiviral drug approved for COVID-19 in Australia, may eventually have a wider application than initially thought.

This month it was approved for the emergency treatment of Australians with severe COVID-19. They receive it by intravenous infusion in hospital.


But now there is growing interest in the potential use of remdesivir by people with less severe symptoms and possibly even for use at home for those with mild symptoms.

Potentially, they would deliver the drug directly into their lungs with an inhaler, like those commonly used for asthma.



This month, Gilead got the green light for use of remdesivir in Australia. AP

This could treat the infection earlier and reduce the likelihood of hospitalisation.



Is your health still covered?

Are you a Senior? You might be missing out on some of these Senior Concessions

Advertisement

LATEST STORIES

Hotels

Capital city hotel revenues down 70pc in June

3 mins ago

Energy

Cooper Energy invests \$55m in Minerva gas plant

13 mins ago

Coronavirus pandemic

Parliament a risky virus 'mixing pot'

15 mins ago

Sharemarket

Enterprise software player Whispir quietly surges to record high

23 mins ago

Australia has deep experience with the development of inhaled antiviral flu drugs and has lessons to share on the roadblocks ahead.


More than 20 years ago, it discovered the flu drug, Relenza, which inhibits viral replication within minutes of arriving in the lungs.

Delivered via an inhaler, it proved effective in both preventing and treating flu, and with much acclaim was marketed globally in 1999.

Gilead Sciences, the Californian company that developed remdesivir, recently started an early phase clinical trial of an inhaled formulation.

"It is testing it for milder disease and may possibly have prophylactic application. Its proposed development echoes the work that was conducted with Relenza," says Dr Phillip Reece, who worked on the drug in Australia.

"Conducting clinical trials with inhaled drugs can be a challenge," says Dr Reece, an honorary senior fellow in the Department of Pharmacology and Therapeutics at Melbourne University.



"Three large phase III clinical trials were initially conducted with Relenza in patients with existing symptoms in the US, Europe and Australia.

The European and Australian trials were positive and highly statistically significant but the US trial was not."


"The reasons for inter-country differences in effectiveness have never been fully explained."

Dr Reece, now a consultant to the biotechnology and pharmaceutical industries, says while a vaccine acts by enhancing the immune response, remdesivir acts by inhibiting viral replication.

"In doing so, it has the potential for use both as a treatment for patients already infected with COVID-19 and as a prophylactic."

While he is impressed with the data so far, he says its potential use for less severe symptoms is based on the assumption that COVID-19 replicates primarily in the lungs, which is not yet clear.

Dr Reece is an affiliate member of the ARC Centre for Personalised Therapeutics Technologies at Melbourne University, of which Professor Alastair Stewart is director.



Despite various challenges, they say inhaled remdesivir currently stands out as the antiviral with the best chance of providing a treatment for COVID-19 in a wider spectrum of patients.

"Inhaled drugs have the advantages of targeted and rapid delivery of smaller doses for conditions limited to the lung and are the mainstay of asthma treatment," says Professor Stewart who is also head of the university's Mechanopharmacology Laboratory.

"Inhaled formulations may be preferred for drugs that don't reach effective lung concentrations or cause adverse effects elsewhere in the body when administered by injections or as tablets," says Professor Stewart supplied.

Trials have shown intravenous remdesivir reduces the duration of symptoms of COVID-19 infection. It hasn't been shown statistically to reduce mortality.

Earlier this month, Federal Health Minister Greg Hunt said Australia has enough remdesivir in the national stockpile thanks to donations made months ago by the drug's makers.

Should inhaled remdesivir be effective, its production of this formulation would have to be massively scaled-up.

Professor Stewart and Dr Reece say the US government's recent purchase of all available stocks of intravenous remdesivir is a salient reminder of the possible challenge ahead.

Fortunately, smaller doses would be required as the drug is expected to be concentrated in lung sputum rather than distributed throughout the body.

How the coronavirus is changing markets, business and politics.

SIGN UP NOW

Coronavirus: Need to know. Our daily reporting, in your inbox.

[Save](#)[Share](#)

License article

READ MORE

[Coronavirus pandemic](#) [Pharmaceuticals](#)

MOST VIEWED IN POLICY

1 NSW 'holding the line' as cases hit April highs

2 Medtech courses to bridge digital health skills gap

3 DFAT cuts show our foreign policy's khaki tinge

4 To lure Hong Kongers, let's import their system

5 Tax shake-up call for super, housing and shares

THE AUSTRALIAN FINANCIAL REVIEW MAGAZINE

BOSS



Your most-missed restaurant dishes – and how to prep them at home

Jill Duplex


How the pandemic changed Healthscope CEO's world overnight

Carrie LaFrenz

Lunch? PwC's chief is far too busy for that

Il changes you can make to become more productive

LIFE & LEISURE



The man who changed fashion forever

Lauren Sams

Why this robot cleaner is almost perfect

Australia's wine industry's 'game spot the black person'

LUXURY



Allbirds adds apparel to its billion-dollar line-up

Lauren Sams

'Welcome to iso island': Qld luxury's new pitch

Anna Thomas was Australian fashion's quiet achiever

© Copyright 2020 The Australian Financial Review

Site Map

The Sydney Morning Herald The Age Domain Drive CarAdvice RSVP Essential Baby Home Price Guide Weatherzone Oneflare

Digital subscription terms Newspaper subscription terms Privacy policy Accessibility Conditions of use Reprints & Permissions

© Copyright 2020 The Australian Financial Review

Site Map

About us

Products & services

Editorial team

Careers

Announcements

Contact

Support

Letters to the editor

Submit a story

Advertise

MAGAZINES

AFR Magazine

BOSS

LUXURY

Life & Leisure

Sophisticated Traveller

Street Talk

Rear Window

The AFR View

Coronavirus pandemic

Pharmaceuticals

MARKETS DATA

Australian indices

World indices

Commodities

Currencies

Derivatives

Interest rates

Companies index

Markets Data FAQs

Power List

Young Rich

Women of Influence

EVENTS

Business Summit

Property Summit

Retail Summit

CFO Live

AFR Future Briefings

AFR Inside Markets

Banking and Wealth Summit

National Infrastructure Summit

Innovation Summit

National Energy Summit

Higher Education Summit

Innovation Summit

Women of Influence

MY ACCOUNT

Recently read

Saved articles

Alerts

Portfolio

Newsletters

Subscriber offers

My account

Log out

SUBSCRIBE

Subscribe

Corporate subscriptions

Student subscriptions